- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.12.24 | BRAIN A/S: Brain+ announces change of Certified Advisor | 2 | Cision News | ||
| 10.12.24 | BRAIN A/S: Brain+ invites to investor webinar to update on UK commercial pipeline and status | 2 | Cision News | ||
| 05.12.24 | BRAIN A/S: Brain+ secures its first multi-year sales contract for Ayla - your CST Assistant with Syddjurs municipality | 4 | Cision News | ||
| 01.11.24 | BRAIN A/S: Brain+ closes new Danish municipality sales contract on Ayla - your CST Assistant | 1 | Cision News | ||
| 21.10.24 | BRAIN A/S: Brain+ progresses UK commercial outreach and hosts the first of a series of webinars on the value of Cognitive Stimulation Therapy | 1 | Cision News | ||
| 11.10.24 | BRAIN A/S: Brain+ unveils new visual brand and website to elevate its Ayla Dementia Care solutions | 1 | Cision News | ||
| 07.10.24 | BRAIN A/S: Brain+ announces first day of trading in new shares from the TO 4 warrant exercise and the related directed issue | 1 | Cision News | ||
| 02.10.24 | BRAIN A/S: Brain+ launches Ayla - your CST Assistant into the UK dementia market | 1 | Cision News | ||
| BRAIN+ A/S Aktie jetzt für 0€ handeln | |||||
| 01.10.24 | BRAIN A/S: Brain+ announces the outcome of its series TO 4 warrant exercise and the decision to carry out a directed share issue to cover guarantor subscriptions | 2 | Cision News | ||
| 25.09.24 | BRAIN A/S: Brain+ confirms imminent commercial launch of Ayla - your CST Assistant as a medical device in the UK | 3 | Cision News | ||
| 23.09.24 | BRAIN A/S: Brain+ informs of three product releases planned for 2025 and introduces a platform renaming as part of its UK commercialization | 2 | Cision News | ||
| 20.09.24 | BRAIN A/S: Brain+ A/S announces additional commitments of DKK 1.4 million in the ongoing TO 4 warrant exercise, which is now covered at 40.4% | 2 | Cision News | ||
| 17.09.24 | BRAIN A/S: Brain+ A/S announces that its board and management provide commitments to cover 13.7% of the warrants of series TO 4 | 1 | Cision News | ||
| 13.09.24 | BRAIN A/S: Brain+ is set to deliver on an ambitious UK commercial plan to reach recurring revenue of DKK 7-8 million by 2025 and DKK 25-27 million by 2027 | 1 | Cision News | ||
| 13.09.24 | BRAIN A/S: Brain+ A/S announces the exercise price for its warrants of series TO 4 | 1 | Cision News | ||
| 05.09.24 | BRAIN A/S: First patient enrolled in a clinical trial to evaluate Brain+' next generation cognitive training technology for Mild Cognitive Impairment | 1 | Cision News | ||
| 29.08.24 | BRAIN A/S: H1 2024: Brain+ has executed successfully in accordance with its UK-focused commercial strategy towards proof-of-business and realized financial results as expected | 2 | Cision News | ||
| 23.08.24 | BRAIN A/S: Brain+ fully on track towards market entry and first sales in the United Kingdom in H2 2024 | 1 | Cision News | ||
| 09.07.24 | First North Denmark: Brain+ A/S - increase and admittance to trading of TO 4 (warrants) | 256 | GlobeNewswire | New shares in Brain+ A/S will be admitted to trading on Nasdaq First North
Growth Market Denmark as per 11 July 2024. New shares are issued due to
completion of a rights issue of units consisting of... ► Artikel lesen | |
| 03.06.24 | First North Denmark: Brain+ A/S - rights issue - admission to trading of Unit Rights | 325 | GlobeNewswire | Unit Rights - UR - in Brain+ A/S will be admitted to trading on Nasdaq First
North Growth Market Denmark as per 7 June 2024. As of the same date, ISIN
DK0061670205 (BRAINP) will be traded exclusive... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRIGHTSPRING HEALTH SERVICES | 20,890 | 0,00 % | BrightSpring Health Services, Inc. Enters into Definitive Agreement to Divest Community Living Business to Sevita; Reports Preliminary 2024 Financial Results and Provides 2025 Guidance Excluding Community Living | Streamlined organization and Provider Services segment to optimize resource allocationProvider Services focus on Home Health/Hospice, Personal Care, Rehabilitation Services, and Care Management strategic... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 54,10 | +0,60 % | Siemens Healthineers-Aktie: Kurs klettert leicht (53,42 €) | Am deutschen Aktienmarkt liegt das Wertpapier von Siemens Healthineers aktuell im Plus. Die Aktie kostete zuletzt 53,42 Euro. Die Aktie von Siemens Healthineers verzeichnet gegenwärtig einen Wertanstieg... ► Artikel lesen | |
| GERRESHEIMER | 65,85 | -1,79 % | EQS-PVR: Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Gerresheimer AG
Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of... ► Artikel lesen | |
| FRESENIUS | 36,260 | +0,14 % | DAX-Check LIVE: Fresenius, Hypoport, Kontron, Lanxess, Nemetschek, Nordex, Porsche AG, RWE, SAP & Co | Der DAX hat gestern die nächste Tausendermarke übersprungen. Erstmalig überwand er 21.000 Punkte. Am Ende des Tages ging er knapp darunter aus dem Handel. Das Tagesplus betrug 0,42 Prozent. Worauf es... ► Artikel lesen | |
| ATRICURE | 39,630 | 0,00 % | Deep Dive Into AtriCure Stock: Analyst Perspectives (9 Ratings) | ||
| PROCEPT BIOROBOTICS | 69,72 | 0,00 % | PROCEPT BioRobotics (NASDAQ:PRCT) Trading Down 2.8% - Should You Sell? | ||
| CARL ZEISS MEDITEC | 48,620 | -0,37 % | DEUTSCHE BANK RESEARCH stuft CARL ZEISS MEDITEC AG auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Carl Zeiss Meditec von 66 auf 55 Euro gesenkt, aber die Einstufung auf "Hold" belassen. Analyst Falko Friedrichs rechnet laut... ► Artikel lesen | |
| GENEDX | 74,33 | 0,00 % | GeneDx Announces Preliminary 2024 Financial Results | STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 44,640 | +0,68 % | Fresenius Medical Care Aktie: Richtung stimmt! | Die Fresenius Medical Care-Aktie setzt ihren positiven Trend fort und verzeichnet am 19. Januar 2025 einen Kursanstieg von 0,04 Prozent auf 44,88 EUR. Die Entwicklung der vergangenen Wochen zeigt eine... ► Artikel lesen | |
| RXSIGHT | 30,920 | 0,00 % | RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance | ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) - RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following... ► Artikel lesen | |
| PROGYNY | 21,470 | 0,00 % | Progyny beruft Gesundheitsexpertin Debra Morris in den Vorstand | ||
| ALIGNMENT HEALTHCARE | 14,555 | 0,00 % | Alignment Healthcare is latest to sue Medicare over Star Ratings | ||
| NANO-X IMAGING | 8,365 | 0,00 % | Nano-X Imaging LTD.: Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication | Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications, in addition to its previously cleared indication... ► Artikel lesen | |
| TREACE MEDICAL CONCEPTS | 9,270 | 0,00 % | Treace Medical Concepts, Inc.: Treace Appoints Guy Guglielmino as Chief Commercial Officer | PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical... ► Artikel lesen | |
| HELIUS MEDICAL | 1,010 | 0,00 % | Helius Medical Technologies, Inc. Announces Strong Enrollment of its Stroke Pivotal Study Exceeding Initial Target | --128 enrolled participants, as of December 31, 2024, exceeds initial target of 90 participants-- --150 maximum participant enrollment projected by end of January-- --The stroke registrational program... ► Artikel lesen |
Das Unternehmen BRAIN+ A/S kann der Branche Gesundheitswesen zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRAIN+ A/S finden Sie auf Wallstreet Online.
